Tejal A. Patel, MD
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Professor (Secondary Appointment), Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, General Oncology, The Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Chief of Service, Medical Oncology MD Anderson Oncology Program at LBJ Hospital, General Oncology, The Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor (Secondary Appointment), Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2003 | University of Texas Medical Branch at Galveston, Galveston, TX, US, Medicine, MD |
Postgraduate Training
| 2006-2009 | Research Fellowship, Hematology Oncology, Mayo Graduate School of Medicine, Jacksonville, Florida |
| 2003-2003 | Clinical Residency, Internal Medicine, Mayo Graduate School of Medicine, Jacksonville, Florida |
Licenses & Certifications
| 2009 | American Board of Internal Medicine in Medical Oncology |
| 2009 | American Board of Internal Medicine Hematology |
| 2008 | Texas Medical Board |
| 2004 | Florida |
Experience & Service
Faculty Academic Appointments
Associate Professor (Secondary Appointment), Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2025
Associate Professor, General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2025
Assistant Professor, Weill Cornell Medical College, Houston, TX, 2012 - 2020
Assistant Professor, Houston Methodist Research, Houston, TX, 2012 - 2020
Instructor, Florida International University Herbert Wertheim College of Medicine, Miami, FL, 2010 - 2012
Instructor, Hematology Oncology, Mayo Clinic, Jacksonville, FL, 2009 - 2010
Administrative Appointments/Responsibilities
Safety and Quality Officer, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present
Chief of Service, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Course Director, Houston Methodist Tumor Boards, Houston, TX, 2018 - 2020
Program Director (authorized GSBS program), Hematology Oncology Fellowship, Houston Methodist Research Institute, Houston, TX, 2016 - 2020
Co-Course Director of Houston Methodist Cancer Symposium, Houston Methodist, Houston, TX, 2014 - 2017
Other Professional Positions
Voting Member, Quality Assurance and Performance Improvement Sub-committee (QAPI), Harris Health, Houston, TX, 2022 - Present
Co-director, Quality Assurance and Performance Improvement Sub-committee (QAPI), Harris Health, Houston, TX, 2022 - Present
Member, LBJ Mortality Review Committee, Houston, TX, 2020 - Present
Voting Member, LBJ Quality Review Council Meetings, Houston, TX, 2020 - Present
Chair, LBJ Faculty Meeting, Houston, TX, 2020 - Present
Member, LBJ Chiefs and Medical Directors Committee, Houston, TX, 2020 - Present
Voting Member, Harris Health Staff Engagement Advisory Council (MSEAC), Houston, TX, 2020 - Present
Co-chair, Beacon Committee at Smith Clinic, Houston, TX, 2020 - Present
Member, LBJ Oncology Steering Committee, Houston, TX, 2020 - Present
Member, Harris Health Cancer Committee, Houston, TX, 2020 - Present
Editorial Activities
Section Editor, Journal of Hematology & Oncology, 2014 - 2015
Honors & Awards
| 2025 | Vicente Valero LBJ Clinician Educator of the Year Award, MD Anderson Division of Cancer Medicine, Hematology Oncology Fellowship |
| 2024 | Vicente Valero LBJ Clinician Educator of the Year Award, MD Anderson Division of Cancer Medicine, Hematology Oncology Fellowship |
| 2023 | Gerald P. Bodey Award for Excellence in Education, MD Anderson Division of Cancer Medicine |
| 2022 | Vicente Valero LBJ Clinical Educator of the Year, MD Anderson Division of Cancer Medicine, Hematology Oncology Fellowship |
| 2021 | Vicente Valero LBJ Clinical Educator of the Year, MD Anderson Division of Cancer Medicine, Hematology Oncology Fellowship |
| 2020 | Vicente Valero LBJ Clinical Educator of the Year, MD Anderson Division of Cancer Medicine, Hematology Oncology Fellowship |
| 2017 - 2019 | Exemplary Teacher for Hematology Oncology, Houston Methodist Hospital Graduate Education Committee |
| 2013 | Winner, Patient Safety Week Debate, Houston Methodist Hospital |
| 2010 | Top Teacher in Hematology-Oncology from Internal Medicine Residents |
| 2006 | The Antonelli Award for Outstanding Senior Resident |
| 2006 | Florida Chapter American College of Physician Award for Outstanding Resident for the year 2006 for excellence in Internal Medicine |
| 2006 | The Golden Apple Award for Outstanding Performance as a Teacher of Clinical Medicine |
| 2005 | Distinguished Physician Florida Medical Association "A Physician Who Cares" |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2017. Cold therapy to prevent chemotherapy induced peripheral neuropathy in breast cancer patients. Conference. Houston Methodist Cancer Symposium. Houston, Texas, US.
- 2016. Advances in metastatic HER2 positive breast cancer. Invited. 4th Annual Cancer Symposium, US.
- 2015. Breast cancer Prevention and Treatment. Invited. Women’s Health Event at Houston Methodist. Houston, TX, US.
- 2013. Selected Topics in Breast Cancer Prevention and Treatment. Invited. The Methodist Hospital System Surgery Grand Rounds, SA.
- 2013. Breast Cancer Prevention and Treatment. Invited. The Methodist Hospital System Medical Oncology Grand Rounds, US.
- 2013. Breast Cancer Prevention and Treatment. Invited. Houston Methodist OB Grand Rounds, US.
- 2013. Breast Cancer Prevention and Treatment. Invited. The Woman’s Hospital of Texas OB Grand Rounds, US.
Regional Presentations
- 2022. Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk. Poster. San Antonio Breast Cancer Symposium, US.
- 2017. The application of a behavior modification clinical solution tool to improve breast cancer survivors’ accountability and health outcomes. Conference. 2017 San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2016. An institution-based care coordination mobile tool for post-hospitalization breast cancer patients. Conference. San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2016. Use of natural language processing on mammography and pathology findings to supplement BI-RADS to improve clinical decision making in breast cancer care. Conference. 2016 San Antonio Breast Cancer Symposium. San Antonio, TX, US.
- 2016. Texas ASCO Program Directors Round table. Invited. Texas ASCO Program Directors Round table. Chicago, IL, US.
- 2015. Cell-free DNA as molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Conference. 2015 SABCS. San Antonio, Texas, US.
National Presentations
- 2023. Overcoming barriers and improving genetic testing completion rate for hereditary cancer in an underserved population at a large safety net hospital,. Poster. 2023 ASCO. Chicago, Illinois, US.
- 2022. Phase IB trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients. Conference. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research. Philadelphia, PA, US.
- 2021. Evaluation of an oncology diagnostic and screening clinic at a large safety net hospital. Poster. 2021 ASCO Quality Care Symposium. Boston, Massachusetts, US.
- 2021. A phase II trial of stereotactic radiation therapy and in situ oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP). Poster. American Society of Clinical Oncology. Chicago, Illinois, US.
- 2020. A Patient Experience and Opinion Using TeleOncology in a Safety-Net Hospital During the Covid 19 Pandemic. Conference. 2020 AACR Virtual Conference. virtual, US.
- 2020. Implementing TeleOncology In a Safety-Net Hospital During the Covid 19 Pandemic. Poster. 2020 ASCO Quality Care Symposium. Chicago, Illinois, US.
- 2019. Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT. Conference. 2019 ASCO. Chicago, Illinois, US.
- 2019. A Phase Ib and II clinical trial investigating the efficacy of nitric oxide deprivation and docetaxel in triple negative breast cancer. Poster. 2019 AACR. Atlanta, GA, US.
- 2019. A phase Ib/II clinical trial investigating the efficacy of nitric oxide deprivation and docetaxel in triple negative breast cancer. Poster. 2019 AACR. Atlanta, GA, US.
- 2019. How to delegate. Invited. ASCO Program Directors Conference 2019. Chicago, IL, US.
- 2018. An Artificial Intelligent Decision Support Tool for Precision Risk Assessment of Breast Cancer. Poster. 2018 AACR, US.
- 2018. A multicenter randomized open label-phase II study of neoadjuvant ado-trastuzumab emtansine (T-DM1), lapatinib and nab paclitaxel versus standard trastuzuamb, pertuzumab and paclitaxel in HER2 over expressed breast cancer patients (TEAL study). Conference. 2018 American Society of Clinical Oncology. Chicago, IL, US.
- 2015. Advances in neoadjuvant therapies for HER2 positive breast cancer. Invited. 25th Annual Mayo Clinic Hematology Oncology Review. Amelia Island, Florida, US.
- 2015. Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel in metastatic HER2-neu overexpressed breast cancer patients: STELA trial results. Poster. 106th Annual Meeting of the American Association for Cancer Research. Philadelphia, PA, US.
- 2014. Phase Ib Trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel (A) in metastatic HER2-neu overexpressed breast cancer patients. Conference. ASCO. Chicago, IL, US.
International Presentations
- 2019. Randomized Parallel-Arm phase II trial of Neoadjvuant Ixabepilone with or without Cetuximab in Patients with Triple Negative Breast Cancer. Poster. 2019 CSCO, CN.
- 2013. Presentations on Advances in Breast Cancer Treatment as well as Complex Breast Cancer Cases. Invited. The Methodist Hospital System Middle East CME in Saudi Arabia, AE.
Selected Publications
Peer-Reviewed Articles
- Johnson Powell, C, Adigwe, A, Ekezie, N, Fatima, B, Majd, Z, Collins, R, Houk, K, Patel, TA, Ma, HY, Shimko, R, Ononogbu, O, Abughosh, S, Trivedi, MV. Interventions to improve adherence to oral endocrine therapy for prevention or treatment of breast cancer in Black women of low socioeconomic status. Supportive Care in Cancer 34(1), 2026. e-Pub 2026. PMID: 41379146.
- Pabon, CM, Wong, J, Perez, M, Jimenez-Abarca, J, Xiao, L, Jackson, L, Park, AK, Lankford, A, Akula, V, Datar, S, Hopper, T, Alkhatib, Y, Earles, T, Patel, TA. Successful posthospitalisation oncology workflow implementing LACE+ score to stratify and reduce readmissions within a safety-net hospital. BMJ Open Quality 14(1), 2025. e-Pub 2025. PMID: 39947738.
- Pabon, CM, Wong, J, Perez, M, Jimenez-Abarca, J, Xiao, L, Jackson, L, Park, AK, Lankford, A, Akula, V, Datar, S, Hopper, T, Alkhatib, Y, Earles, T, Patel, TA. Successful posthospitalisation oncology workflow implementing LACE+ score to stratify and reduce readmissions within a safety-net hospital. BMJ Open Quality 14(1), 2025. e-Pub 2025. PMID: 39947738.
- Kizub DA, Raber M, Baum M, Ma HY, Patel TA, Rechis R, LaRue DM, Ho-Pham TT, Oestman K, Walsh MT Jr, Galvan E, Basen-Engquist K. Patient and Health Care Professional Perspectives on Barriers to and Facilitators of Healthy Eating and Exercise Among Patients With Cancer at a Safety-Net Oncology Clinic: A Qualitative Exploration. JCO Oncol Pract 21(7):OP2400431, 2025. e-Pub 2025. PMID: 39847732.
- Puri, A, Yin, Z, Granados-Principal, S, Ensor, J, Guzman, L, Rosato, RR, Zhao, H, Wong, ST, Wang, L, Patel, TA, Chang, J. Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk of Cancer. International Journal of Breast Cancer 2025(1), 2025. e-Pub 2025. PMID: 39882028.
- Jayan A, Sukumar JS, Fangman B, Patel T, Raghavendra AS, Liu D, Pasyar S, Rauch R, Basen-Engquist K, Tripathy D, Wang Y, Khan SS, Barcenas CH. Real-World Immune-Related Adverse Events in Patients With Early Triple-Negative Breast Cancer Who Received Pembrolizumab. JCO Oncol Pract 21(9):1265-1273, 2024. e-Pub 2024. PMID: 39388649.
- Denu, RA, McDermott, JJ, Patel, SC, Patel, TA, Dahr, SS. Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer. Case Reports in Oncology 17(1):1071-1086, 2024. e-Pub 2024. PMID: 39474530.
- Ezeana CF, He T, Patel TA, Kaklamani V, Elmi M, Brigmon E, Otto PM, Kist KA, Speck H, Wang L, Ensor J, Shih YT, Kim B, Pan IW, Cohen AL, Kelley K, Spak D, Yang WT, Chang JC, Wong STC. A Deep Learning Decision Support Tool to Improve Risk Stratification and Reduce Unnecessary Biopsies in BI-RADS 4 Mammograms. Radiol Artif Intell 5(6):e220259, 2023. e-Pub 2023. PMID: 38074778.
- Sun K, Xu Y, Zhang L, Niravath P, Darcourt J, Patel T, Teh BS, Farach AM, Guerrero C, Mathur S, Sultenfuss MA, Gupta N, Schwartz MR, Haley SL, Nair S, Li X, Nguyen TTA, Butner JD, Ensor J, Mejia JA, Mei Z, Butler EB, Chen SH, Bernicker EH, Chang JC. A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res 28(20):4392-4401, 2022. e-Pub 2022. PMID: 35877117.
- Puri A, Mylavarapu C, Xu J, Patel TA, S Teh B, Tremont-Lukats I, Chang JC, Niravath P. Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases. Breast Cancer Res Treat 193(3):613-623, 2022. e-Pub 2022. PMID: 35460498.
- Chung AW, Anand K, Anselme AC, Chan AA, Gupta N, Venta LA, Schwartz MR, Qian W, Xu Y, Zhang L, Kuhn J, Patel T, Rodriguez AA, Belcheva A, Darcourt J, Ensor J, Bernicker E, Pan PY, Chen SH, Lee DJ, Niravath PA, Chang JC. A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer. Sci Transl Med 13(624):eabj5070, 2021. e-Pub 2021. PMID: 34910551.
- Tennison JM, Fricke BC, Fu JB, Patel TA, Chen M, Bruera E. Medical Complications and Prognostic Factors for Medically Unstable Conditions During Acute Inpatient Cancer Rehabilitation. JCO Oncol Pract 17(10):e1502-e1511, 2021. e-Pub 2021. PMID: 33683918.
- Koca E, Niravath PA, Ensor J, Patel TA, Li X, Hemati P, Wong H, Qian W, Boone T, Zhao J, Ramshesh PV, Cohen AL, Murthy A, Nair S, Darcourt JG, Belcheva A, Kaklamani VG, Chang JCN. ANETT: PhAse II trial of NEoadjuvant TAK-228 plus Tamoxifen in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat 188(2):433-439, 2021. e-Pub 2021. PMID: 33860388.
- Burns E, Koca E, Xu J, McLean E, Lee R, Patel T, Chang J, Niravath P. Measuring Ovarian Escape in Premenopausal Estrogen Receptor-Positive Breast Cancer Patients on Ovarian Suppression Therapy. Oncologist 26(6):e936-e942, 2021. e-Pub 2021. PMID: 33594769.
- Anand K, Niravath P, Patel T, Ensor J, Rodriguez A, Boone T, Wong ST, Chang JC. A Phase II Study of the Efficacy and Safety of Chloroquine in Combination With Taxanes in the Treatment of Patients With Advanced or Metastatic Anthracycline-refractory Breast Cancer. Clin Breast Cancer 21(3):199-204, 2021. e-Pub 2021. PMID: 34159901.
- Anand K, Patel T, Niravath P, Rodriguez A, Darcourt J, Belcheva A, Boone T, Ensor J, Chang J. Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy. Sci Rep 11(1):82, 2021. e-Pub 2021. PMID: 33420229.
- Jaeckle KA, Dixon JG, Anderson SK, Moreno-Aspitia A, Colon-Otero G, Hebenstreit K, Patel TA, Reddy SL, Perez EA. Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases. Cancer Med 9(21):7935-7942, 2020. e-Pub 2020. PMID: 32885617.
- Puri A, Reddy TP, Patel TA, Chang JC. Metastatic Triple-Negative Breast Cancer: Established and emerging treatments. Breast J 26(9):1793-1796, 2020. e-Pub 2020. PMID: 32578306.
- Lewis GD, Xing Y, Haque W, Patel T, Schwartz MR, Chen AC, Farach A, Hatch SS, Butler EB, Chang JC, Teh BS. The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast. Breast J 25(6):1171-1176, 2019. e-Pub 2019. PMID: 31321854.
- Lewis GD, Xing Y, Haque W, Patel T, Schwartz M, Chen A, Farach A, Hatch SS, Butler EB, Chang J, Teh BS. Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. Cancer Commun (Lond) 39(1):60, 2019. e-Pub 2019. PMID: 31639071.
- Patel TA, Ensor JE, Creamer SL, Boone T, Rodriguez AA, Niravath PA, Darcourt JG, Meisel JL, Li X, Zhao J, Kuhn JG, Rosato RR, Qian W, Belcheva A, Schwartz MR, Kaklamani VG, Chang JC. A randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study). Breast Cancer Res 21(1):100, 2019. e-Pub 2019. PMID: 31477168.
- He T, Puppala M, Ezeana CF, Huang YS, Chou PH, Yu X, Chen S, Wang L, Yin Z, Danforth RL, Ensor J, Chang J, Patel T, Wong STC. A Deep Learning-Based Decision Support Tool for Precision Risk Assessment of Breast Cancer. JCO Clin Cancer Inform 3:1-12, 2019. e-Pub 2019. PMID: 31141423.
- Messer JA, Ekinci E, Patel TA, Teh BS. Enhanced dermatologic toxicity following concurrent treatment with palbociclib and radiation therapy: A case report. Rep Pract Oncol Radiother 24(3):276-280, 2019. e-Pub 2019. PMID: 30948930.
- Stubbins R, He T, Yu X, Puppala M, Ezeana CF, Chen S, Valdivia Y Alvarado M, Ensor J, Rodriguez A, Niravath P, Chang J, Wong STC, Patel T. A Behavior-Modification, Clinical-Grade Mobile Application to Improve Breast Cancer Survivors' Accountability and Health Outcomes. JCO Clin Cancer Inform 2:1-11, 2018. e-Pub 2018. PMID: 30652617.
- Patel TA, Puppala M, Ogunti RO, Ensor JE, He T, Shewale JB, Ankerst DP, Kaklamani VG, Rodriguez AA, Wong ST, Chang JC. Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods. Cancer 123(1):114-121, 2017. e-Pub 2017. PMID: 27571243.
- Liang DH, Ensor JE, Liu ZB, Patel A, Patel TA, Chang JC, Rodriguez AA. Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients. Breast Cancer Res Treat 155(1):139-49, 2016. e-Pub 2016. PMID: 26667234.
- Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Erratum: Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 16(6):468, 2014. e-Pub 2014. PMID: 25927825.
- Moreno-Aspitia A, Dueck AC, Ghanem-Canete I, Patel TA. RCO639: A phase II study of Paclitaxel, Trastuzumab and Lapatinib as adjuvant therapy for early stage HER2 positive breast cancer. Breast Cancer Res Treat, 2013. e-Pub 2013.
- Perez EA, Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Breast Cancer Res Treat, 2013. e-Pub 2013.
- Patel TA, Colon-Otero G, Hume CB, JArd C, Perez EA. Breast Cancer in Latinas: Gene Expression, Differential Response to Treatments, and Differential Toxicities in Latinas Compared with Other Population Groups. The Oncologist, 2010. e-Pub 2010.
- Saurel CA, Patel TA, Perez, EA. Changes to Adjuvant Systemic Therapy in Breast Cancer. A Decade in Review. Clinical Breast Cancer, 2010. e-Pub 2010.
- Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC. N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. North Central Cancer Treatment Group, 2009. e-Pub 2009.
Review Articles
- Jayan, A, Sukumar, J, Fangman, B, Patel, TA, Singareeka Raghavendra, A, Liu, D, Rauch, RA, Basen-Engquist, KM, Tripathy, D, Barcenas, CH. Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab. Journal of Clinical Oncology 42:1099, 2024. e-Pub 2024.
- Patel TA, Dave B, Rodriguez AA, Chang JC, Perez EA, Colon-Otero G. Dual HER2 blockade: preclinical and clinical data. Breast Cancer Res 16(4):419, 2014. e-Pub 2014. PMID: 25928889.
Abstracts
- Patel T, Mejia J, Rodriguez A, Chang J. Phase Ib trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel (A) in metastatic HER2-neu overexpressed breast cancer patients: STELA trial results. AACR 75(15), 2015. e-Pub 2015.
- Patel TA, Mejia JA, Rodriguez AA, Boone TA, Chang JC. Phase Ib Trial of trastuzumab emtansine (TE) in combination with lapatinib (L) plus nab-paclitaxel (A) in metastatic HER2-neu overexpressed breast cancer patients: Stela Trial (NCT02073916). J Clin Oncol 32:15:1035 - 1035, 2014. e-Pub 2014.
Book Chapters
- Hui D, Leung AA, Ma C. Oncology. In: Approach to Internal Medicine 5ed Oncology Section, 2022.
Patient Reviews
CV information above last modified July 22, 2026